Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
glaxosmithkline
5
×
ipo
5
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
indiana blog main
indiana top stories
allergan
clinical trials
crispr
medical devices
scott gottlieb
abbvie
amgen
biogen
black diamond therapeutics
What
bio
5
×
roundup
black
cancer
crispr
diamond’s
drugs
moves
therapeutics
week
allogene
appetite
august
big
biotech
bosley's
bosley’s
bread
bridge
bucks
busy
butter
buyout
cas
cash
ceo
companies
continue
crime
days
debut
decisions
departure
devices
diabetes
diamond
diversity
editas
eli
exit
Language
unset
Current search:
glaxosmithkline
×
bio
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
